14 completed, 6 recruiting, 5 terminated, 2 unknown. 28 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 14, Recruiting 6, Terminated 5, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 14 | Completed 6, Recruiting 4, Terminated 3, Not yet recruiting 1 |
Follow Muscle Hypertonia: new trials by email Literature Review of Muscle Hypertonia trials Research Report on Muscle Hypertonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Use of Photobiomodulation in the Treatment of Spasticity After Stroke. Photobiomodulation Therapy, Placebo PBM, Standard Multidisciplinary Rehabilitation Program for Spasticity - Stroke, Spasticity | Phase 1 / Phase 2 | Recruiting | University of Nove de Julho | 42 | 2026-08-28 | 2026-09-01 |
| Shockwave for Elbow and Wrist Spasticity in People With Spinal Cord Injury Focused extracorporeal shockwave therapy - Spinal Cord Injury, Spasticity | Phase 1 | Recruiting | Kessler Foundation | 12 | 2026-03-06 | 2026-10-22 |
| Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms Transcranial Electrical Stimulation Device - PARKINSON DISEASE (Disorder) | Phase 1 / Phase 2 | Recruiting | U: The Mind Company | 30 | 2026-01-01 | 2026-01-27 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) ALN-SNCA, Placebo - Parkinsons Disease | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 46 | 2025-12-05 | 2026-09-21 |
| Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) BFB-101 (AAV9-CBh-AP4B1) - HSP, Hereditary Spastic Paraplegia | Phase 1 / Phase 2 | Not yet recruiting | BlackfinBio Ltd | 5 | 2025-08-01 | 2025-04-28 |
| Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity ABBV-950, BOTOX, Placebo for ABBV-950 - Upper Limb Spasticity | Phase 1 | Terminated | AbbVie | 1 | 2024-01-12 | 2024-07-01 |
| Effects of Marijuana on Neuropathic Pain and Spasticity in Spinal Cord Injury Patients Cannabis, Placebo - Spinal Cord Injury | Phase 1 | Unknown | Khon Kaen University | 20 | 2024-01-02 | 2024-03-08 |
| Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals MTR-601 - Muscle Spasticity, Hypertonia, Muscle | Phase 1 | Completed | Motric Bio | 89 | 2023-09-11 | 2026-06-05 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. Corabotase, Placebo, Dysport - Spasticity | Phase 1 / Phase 2 | Recruiting | Ipsen | 240 | 2021-04-29 | 2026-07-28 |
| CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1) CORETOX®, BOTOX® - Muscle Spasticity | Phase 1 | Completed | Medy-Tox | 30 | 2017-07-17 | 2022-01-11 |
| The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke sham Doublestim, anodal Doublestim - Stroke, Cerebrovascular Accident (CVA) | Phase 1 / Phase 2 | Completed | Northwell Health | 26 | 2016-09-01 | 2021-04-05 |
| Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT shock waves, Botulinum Toxin Type A - Spasticity, Cerebral Palsy | Phase 1 | Completed | Xavi Vidal Novellas | 70 | 2014-09-01 | 2017-03-13 |
| Multichannel tDCS to Reduce Hypertonia in Patients With Prolonged DOC tDCS, sham tDCS - Vegetative State, Minimally Conscious State | Phase 1 | Completed | University of Liege | 17 | 2014-01-20 | 2019-01-09 |
| Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers Intravenous baclofen - Safety and Pharmacokinetics of Intravenous Baclofen | Phase 1 | Completed | University of Minnesota | 39 | 2014-01-01 | 2019-05-07 |
| Oral and IV Baclofen in Adult Volunteers Oral baclofen, Intervenous baclofen - Baclofen Withdrawal Syndrome | Phase 1 | Completed | University of Minnesota | 12 | 2013-01-01 | 2014-08-05 |
| The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI) LOKOMAT - Motor Complete Spinal Cord Injury | Phase 1 / Phase 2 | Completed | Dr. Gabriel Zeilig | 11 | 2011-05-01 | 2016-12-28 |
| Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity baclofen - Spasticity, Cerebral Palsy | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 61 | 2008-11-01 | 2011-12-06 |
| Botulinum Toxin Injection Efficiency Resistance training - Torticollis, Muscle Spasticity | Phase 1 | Unknown | Jyväskylä Central Hospital | 22 | 2008-09-01 | 2009-12-31 |
Showing 20 of 28. Sign in to see all of them.
Muscle Spasticity (25) · Multiple Sclerosis (6) · Cerebral Palsy (4) · Marijuana Abuse (4) · Stroke (4) · Muscle Rigidity (3) · Spinal Cord Injuries (3) · Brain Injuries, Traumatic (2) · Pain (2) · Paraplegia (2) · Parkinson Disease (2) · Spastic Paraplegia, Hereditary (2) · Tremor (2) · Cognitive Dysfunction (1)
Muscular Diseases (28) · Musculoskeletal Diseases (28) · Nervous System Diseases (28) · Neurologic Manifestations (28) · Neuromuscular Manifestations (28) · Pathological Conditions, Signs and Symptoms (28) · Signs and Symptoms (28) · Central Nervous System Diseases (16) · Brain Diseases (12) · Autoimmune Diseases (7) · Autoimmune Diseases of the Nervous System (7) · Immune System Diseases (7) · Mental Disorders (7) · Demyelinating Autoimmune Diseases, CNS (6)
Botulinum Toxins, Type A (3) · Baclofen (2) · nabiximols (2) · ADX-629 (1) · Administration, Sublingual (1) · Dronabinol (1) · Immunoglobulins, Intravenous (1) · Low-Level Light Therapy (1) · Resistance Training (1) · Transcranial Direct Current Stimulation (1) · abobotulinumtoxinA (1) · coretox (1) · tizanidine (1)
Teva GTC (3) · Center for Medicinal Cannabis Research (2) · University of Minnesota (2) · AbbVie (1) · BlackfinBio Ltd (1) · Dr. Gabriel Zeilig (1) · Elpida Therapeutics SPC (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Ipsen (1) · Jyväskylä Central Hospital (1) · Kessler Foundation (1) · Khon Kaen University (1) · Medy-Tox (1) · Motric Bio (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (17) · Israel (4) · South Korea (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Italy (1)
Arnon Karni, MD (2) · Alan Hand, MD (1) · Gabriel Zeilig, M.D (1) · Ido Yatsiv, MD (1) · James C Cloyd, PharmD (1) · Janice Brunstrom, MD (1) · Jari Ylinen, MD, PhD (1) · Jody Corey-Bloom, M.D., Ph.D. (1) · Linda E Krach, MD (1) · Mark Agius, M.D. (1) · Michelle Apperson, MD, PhD (1)
PMID 41491634, PMID 24607242, PMID 28867665, PMID 32232101
2025 (1)